SCHEMBL14981963

SCHEMBL14981963

NCCCCN(O)C(=O)CCC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 12/20 0.62
KDM4C Q9H3R0 11/20 0.62
HIF1A Q16665 1/20 0.53
TET2 Q6N021 1/20 0.53
DOHH Q9BU89 1/20 0.53
CYP2D6 P10635 1/20 0.52
NFKB1 P19838 1/20 0.52
LMNA P02545 3/20 0.50
BLM P54132 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
THRB P10828 2/20 0.50
KMT2A Q03164 2/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
PLG P00747 1/20 0.50
ALOX15 P16050 1/20 0.50
SLC6A2 P23975 1/20 0.50
RECQL P46063 1/20 0.50
SLC6A3 Q01959 1/20 0.50
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18951965 0.98 KDM4A (0.66) KDM4AKDM4CHIF1ATET2DOHH
SCHEMBL18951929 0.98 KDM4A (0.66) KDM4AKDM4CHIF1ATET2DOHH
SCHEMBL18951933 0.89 LMNA (0.57) KDM4AKDM4CHIF1ATET2DOHH
SCHEMBL18951963 0.85 MEN1 (0.63) KDM4AKDM4CCYP2D6NFKB1LMNA
SCHEMBL30632629 0.84 KDM4A (0.78) KDM4AKDM4CHIF1ATET2DOHH
SCHEMBL30627429 0.84 KDM4A (0.78) KDM4AKDM4CHIF1ATET2DOHH
SCHEMBL18952066 0.82 KDM4C (0.66) KDM4AKDM4CLMNATHRBKMT2A
SCHEMBL29579829 0.82 KDM4A (0.55) KDM4AKDM4CHIF1ATET2DOHH
SCHEMBL18970370 0.82 KDM4C (0.66) KDM4AKDM4CLMNATHRBKMT2A
SCHEMBL17900846 0.81 KDM4A (0.61) KDM4AKDM4CHIF1ATET2DOHH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119212692-A Biotechnological production of monomers of specific Su Kalin, deferoxamine and analogues thereof 赢创运营有限公司 2024-12-27 CN claimed
EP-4525843-A1 BIOTECHNOLOGICAL PRODUCTION OF MONOMERS OF BISUCABERINS, DESFERRIOXAMINES AND ANALOGS THEREOF Evonik Operations GmbH (DE) 2025-03-26 EP disclosed
CN-119212692-A Biotechnological production of monomers of specific Su Kalin, deferoxamine and analogues thereof 赢创运营有限公司 2024-12-27 CN disclosed
US-8735622-B2 Histone demethylase inhibitors and methods for using the same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2014-05-27 US disclosed
US-8735622-B2 Histone demethylase inhibitors and methods for using the same THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2014-05-27 US disclosed
US-20130137720-A1 HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME The Regents of the University of Colorado, a body corporated (US) 2013-05-30 US disclosed
US-20130137720-A1 HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME The Regents of the University of Colorado, a body corporated (US) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137720-A1 HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME KDM1A, KDM3A, KDM7A KDM4A 9/4885KDM4C 18/4885HIF1A 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.